Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers

被引：53

作者：

Pillow, Thomas H. ^{[1
]}

Schutten, Melissa ^{[1
]}

Yu, Shang-Fan ^{[1
]}

Ohri, Rachana ^{[1
]}

Sadowsky, Jack ^{[1
]}

Poon, Kirsten Achilles ^{[1
,4
]}

Solis, Willy ^{[1
,5
]}

Zhong, Fiona ^{[1
]}

Del Rosario, Geoffrey ^{[1
]}

Go, Mary Ann T. ^{[1
]}

Lau, Jeffrey ^{[1
]}

Yee, Sharon ^{[1
]}

He, Jintang ^{[1
]}

Liu, Luna ^{[1
]}

Ng, Carl ^{[1
]}

Xu, Keyang ^{[1
]}

Leipold, Douglas D. ^{[1
]}

Kamath, Amrita V. ^{[1
]}

Zhang, Donglu ^{[1
]}

Masterson, Luke ^{[2
]}

Gregson, Stephen J. ^{[2
]}

Howard, Philip W. ^{[2
]}

Fang, Fan ^{[3
]}

Chen, Jinhua ^{[3
]}

Gunzner-Toste, Janet ^{[1
]}

Kozak, Katherine K. ^{[1
]}

Spencer, Susan ^{[1
]}

Polakis, Paul ^{[1
]}

Polson, Andrew G. ^{[1
]}

Flygare, John A. ^{[1
]}

Junutula, Jagath R. ^{[1
,6
]}

机构：

[1] Genentech Inc, San Francisco, CA 94030 USA

[2] Spirogen Ltd, QMBInnovat Ctr, London, England

[3] WuXi AppTec Co Ltd, Shanghai, Peoples R China

[4] Denali Therapeut, San Francisco, CA USA

[5] Bristol Myers Squibb, Princeton, NJ USA

[6] Cellerant Therapeut, San Carlos, CA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2017年 / 16卷 / 05期

关键词：

BIOLOGICAL EVALUATION; TARGETED TREATMENT; CANCER-THERAPY; IN-VIVO; DESIGN; CHEMISTRY; SELECTION; STABILITY; LYMPHOMA; DELIVERY;

D O I：

10.1158/1535-7163.MCT-16-0641

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs). ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker. Both the chemical linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC. This novel disulfide ADC was compared with a conjugate containing the same PBD drug, but attached to the antibody via a peptide linker. Both ADCs had similar efficacy in mice bearing human tumor xenografts. Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC. Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equivalent efficacy and improved safety. (C) 2017 AACR.

引用

页码：871 / 878

页数：8

共 50 条

[21] From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
Mantaj, Julia
Jackson, Paul J. M.
Rahman, Khondaker M.
Thurston, David E.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (02) : 462 - 488
[22] Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates
Thomas, Joshua D.
Yurkovetskiy, Aleksandr, V
Yin, Mao
Bodyak, Natalya D.
Gumerov, Dmitry R.
Tang, Shuyi
Kelleher, Eoin
Jones, Brian D.
Protopopova, Marina
Qin, LiuLiang
Uttard, Alex
Demady, Damon R.
Lowinger, Timothy B.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 72
[23] Development of pyrrolobenzodiazepine-based antibody-drug conjugates for cancer.
Jeffrey, Scott C.
Burke, Patrick J.
Sutherland, May K.
Meyer, David W.
Lyon, Robert P.
McEarchern, Julie A.
Law, Che-Leung
Senter, Peter D.
CANCER RESEARCH, 2013, 73 (08)
[24] Self-Immolative Linkers Literally Bridge Disulfide Chemistry and the Realm of Thiol-Free Drugs
Riber, Camilla Frich
Smith, Anton A. A.
Zelikin, Alexander N.
ADVANCED HEALTHCARE MATERIALS, 2015, 4 (12) : 1887 - 1890
[25] Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates
Burke, Patrick J.
Hamilton, Joseph Z.
Pires, Thomas A.
Setter, Jocelyn R.
Hunter, Joshua H.
Cochran, Julia H.
Waight, Andrew B.
Gordon, Kristine A.
Toki, Brian E.
Emmerton, Kim K.
Zeng, Weiping
Stone, Ivan J.
Senter, Peter D.
Lyon, Robert P.
Jeffrey, Scott C.
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 938 - 945
[26] Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates
Balamkundu, Seetharamsing
Liu, Chuan-Fa
BIOMEDICINES, 2023, 11 (11)
[27] Sulfatase-cleavable linkers for antibody-drug conjugates (ADCs)
Bargh, Jonathan
Walsh, Stephen
Isidro-Llobet, Albert
Spring, David
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
[28] Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates
Jeffrey, SC
Andreyka, JB
Bernhardt, SX
Kissler, KM
Kline, T
Lenox, JS
Moser, RF
Nguyen, MT
Okeley, NM
Stone, IJ
Zhang, XQ
Senter, PD
BIOCONJUGATE CHEMISTRY, 2006, 17 (03) : 831 - 840
[29] Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates
Dal Corso, Alberto
Cazzamalli, Samuele
Gebleux, Remy
Mattarella, Martin
Neria, Dario
BIOCONJUGATE CHEMISTRY, 2017, 28 (07) : 1826 - 1833
[30] Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
Hartley, John A.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 931 - 943

← 1 2 3 4 5 →